Plain-English translation of NCT07455032 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether CADI-05, a new experimental medication, works better when combined with (a standard immunotherapy drug already approved by the FDA) for treating locally advanced head and neck squamous cell cancer. Researchers want to see if this combination helps your immune system fight the cancer more effectively before surgery, and they want to understand any side effects the medication might cause.
Head and neck cancers are serious, and doctors are looking for ways to shrink tumors before surgery to improve patient outcomes. This trial explores whether adding this new treatment to standard care could be more effective than surgery alone.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every week for 5 weeks. During this time, you would receive two infusions of (through a vein in your arm) and five weekly injections of the experimental medication under your skin. You would also have blood tests and checkups at each visit. After 5–6 weeks, you would have your planned surgery to remove the cancer. Finally, you would return for one follow-up visit about a month after surgery.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States